What is CordenPharma’s climate strategy?
We aim to work for 100 percent renewable electricity at all CordenPharma sites. In addition, we are investing to improve our production processes to make them more efficient and to use our resources, and finally, we are looking to engage with all our suppliers, so they establish carbon reduction targets to support our objectives.
Together, collectively, we aim to provide more transparency to our customers and employees on our objectives and how we intend to meet those objectives over the next years.
Why the Science Based Targets initiative (SBTi)?
The Science-Based Targets initiative allows a simple, measurable, and standardized way to achieve our objectives and manage the change we need to do. In addition, it fulfils our ambition to be a leader in climate action and to be the partner our customers need as a CDMO.
What will happen in 2025?
By joining the SBTi, we committed to a two-year measurement of our carbon footprint. We have selected reduction targets and submitted them for validation. This year we will also publish our very first sustainability report, which will show our customers and employees exactly where we are and where we want to go in the next years. This is an important milestone in our sustainability journey.
How supportive is our shareholder Astorg?
The Science Based Targets initiative is part of Astorg’s sustainability program and their ownership strategy for their portfolio of companies. It’s an important part of how they create value at CordenPharma. We have received full support of our investors, and we couldn’t be more united to achieve these targets together over the next years.
How will we hear updates on this journey?
We aim to provide a series of touchpoints to update our customers on our progress. We will do this from our global teams and across our facility network.
William Cashin
Chief Quality & Compliance Officer
Get in touch with our team of experts to explore bespoke end-to-end CDMO support of your complete drug lifecycle
at any scale.